# PATIENT ALERT CARD

**Have this card with you at all times**

KYMRIAH®▼
(tisagenlecleucel) Dispersion for IV infusion

▼ This medicinal product is subject to additional monitoring. If you get any side effects, talk to your doctor, pharmacist or nurse. By reporting side effects, you can help provide more information on the safety of this medicine. You can report side effects directly via HPRA Pharmacovigilance on www.hpra.ie. Side effects could also be reported to Novartis preferably via **www.report.novartis.com**, or by email to **drugsafety.dublin@novartis.com** or by calling **01 2080 612**.

HPRA approved August 2020

NOVARTIS

IE02/KYM20-CNF012c
Date of Preparation: June 2020

## INFORMATION FOR THE HEALTHCARE PROVIDER

This patient has received KYMRIAH (tisagenlecleucel), an autologous CAR-T cell therapy.

**This patient should not donate blood, organs, tissues, or cells**.

**BEFORE PROVIDING ANY TREATMENT, CALL THE TREATING CLINICIAN AT THE NUMBER PROVIDED OPPOSITE**

When reporting possible side effects, please include the individual Batch ID printed on patient information opposite.

HPRA approved August 2020

## PATIENT INFORMATION

I have been treated with KYMRIAH, an immunocellular therapy containing genetically modified autologous T cells.

**MY NAME IS:** _____

**BATCH ID:** _____

**DATE OF TREATMENT:** _____

**KYMRIAH TREATING CLINICIAN DETAILS** (name & phone no.)**:**

_____

**I should not donate blood, organs, tissues, or cells.**